Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. Summary
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
4800 4718 4725 4652 4648 Last
607500 566500 608200 603600 664500 Volume
-1.03% -1.71% +0.15% -1.54% -0.09% Change
Estimated financial data (e)
Sales 2021 1 467 B 12 897 M 12 897 M
Net income 2021 161 B 1 412 M 1 412 M
Net cash position 2021 285 B 2 506 M 2 506 M
P/E ratio 2021 15,6x
Yield 2021 2,17%
Sales 2022 1 508 B 13 263 M 13 263 M
Net income 2022 159 B 1 397 M 1 397 M
Net cash position 2022 363 B 3 193 M 3 193 M
P/E ratio 2022 15,7x
Yield 2022 2,23%
Capitalization 2 521 B 22 170 M 22 170 M
EV / Sales 2021 1,52x
EV / Sales 2022 1,43x
Nbr of Employees 33 151
Free-Float 75,4%
More Financials
Company
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (64.4% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale... 
Sector
Pharmaceuticals
Calendar
11/12Earnings Release
More about the company
Ratings of Otsuka Holdings Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about OTSUKA HOLDINGS CO., LTD.
10/07PRESS RELEASE : Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relati..
DJ
10/06OTSUKA : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the T..
BU
10/06LUPIN : Gets US FDA's Approval for Brexpiprazole Tablets
MT
10/04Sumitomo Dainippon Sells License for Psychiatry and Neurology Compounds to Otsuka for $..
MT
09/30Health Care Stocks Closing Slightly Lower After Early Gains
MT
09/30Health Care Stocks Unable to Sustain Early Rise
MT
09/30OPTIMIZERX : Hires Edward Stelmakh as CFO, COO
MT
09/30OTSUKA : Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and Licen..
PU
09/28Mcquade Center for Strategic Research and Development Launches the Otsuka Digital Pione..
CI
08/30UNIVERSAL DISPLAY : Unit Adesis Appoints Linda Choi MacDonald as COO
MT
08/16PRESS RELEASE : atai Life Sciences Reports Second Quarter 2021 Financial Results and Busin..
DJ
08/10NIKKEI 225 : Japanese Shares End Flat in Positive Territory on Trade Balance Data
MT
08/10Otsuka Holdings' Attributable Profit Rises 5.3% in January to June; Shares Jump 6%
MT
08/10Japan shares ride earnings to end higher, Delta worries linger
RE
08/09Japanese stocks rise on strong earnings; Delta worries linger
RE
More news
News in other languages on OTSUKA HOLDINGS CO., LTD.
10/20MODERN PLANT BASED FOODS INC. : Modern Plant Based Foods Inc. ernennt Anastasia Bogomolova..
10/06Lupin obtient l'approbation de la FDA américaine pour les comprimés de Brexpiprazole
09/30Les actions du secteur de la santé clôturent en légère baisse après des gains initiaux
09/30Les actions du secteur de la santé ne parviennent pas à maintenir leur hausse initiale
08/30L'unité d'affichage universel Adesis nomme Linda Choi MacDonald au poste de directrice ..
More news
Chart OTSUKA HOLDINGS CO., LTD.
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | 4578 | JP3188220002 | MarketScreener
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 4 648,00 JPY
Average target price 4 741,67 JPY
Spread / Average Target 2,02%
EPS Revisions
Managers and Directors
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Chief Financial Officer & Director
Ichiro Otsuka Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director